The aim of our study was to evaluate the functional peculiarities of the respiratory system and the dynamics of IL-6 in patients with infiltrative tuberculosis combined with chronic bronchitis.
Materials and methods. There were examined 40 patients with infiltrative tuberculosis combined with chronic bronchitis: 18 patients receiving basic therapy according to the category and 22 patients who were added glucosaminilemuramylpentapeptide to basic therapy. Determination of IL-6 in bronchoalveolar content was performed by ELISA analysis.
Results. The additional inclusion of glucosaminilemuramylpentapeptide into the complex therapy of patients with infiltrative tuberculosis combined with chronic bronchitis in acute phase manifests itself with positively aimed dynamic changes of the bronchial mucous membrane according to the data of endoscopy. The standard scheme of treatment combined with immune modulator affects the recovery of lung function in comorbidity of pathologies explaining it as the action of the means aimed at enhancing of sanogenetic mechanisms of liquidation of combination of specific and nonspecific inflammation in the broncho-pulmonary system, and thus – the reduction of the basis for secondary bronchial obstruction. The results of this study indicate the advisability of administration of immune modulator of muramylpeptide series.
Feshchenko YuI, Melnyk VM, Zaykov SV, Veselovskyy LV, Lynnyk MI.Peculiarities of the current tuberculosis epidemiological situation in Ukraine. Ukrayinsky pulmonolohichny zhurnal. 2016;1:5–9.
Feshchenko YuI, Ishchuk SH, Matvienko YuA. Therapeutic possibilities of the innovative immunomodulator in pulmonology and phthisiology. Ukrayinsky pulmonolohichny zhurnal. 2012;3:50–54.
Feshchenko YuI, Cherenko SO. Control of tuberculosis in Ukraine today Tuberkuloz. Lehenevi khvoroby. VIL-infektsiya. 2010; 3:5-13.
Cherenko SO. Immunepathogenesis of pulmonary tuberculosis. Astma ta alerhiya. 2013; 1:32-37.
Chernushenko EF, Protsiuk RH. Antituberculous immunity (Part I). Ukrayinsky pulmonolohichny zhurnal. 2010; 4:53–58.
Chernushenko EF, Protsiuk RH. Antituberculous immunity (Part II). Ukrayinsky pulmonolohichny zhurnal. 2011; 1:29–32
Chernushenko EF, Kadan LP, Panasiukova OR, Petishkina OR, Tsygankova LM. Cytokines in the evaluation of the immunity system in patients with lung tuberculosis. Ukrayinsky pulmonolohichny zhurnal. 2010; 2:39-49.
Bhattacharya D, Dwivedi VP, Maiga M, Van Kaer L, Bishai WR, Das G. Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis*. THE JOURNAL OF BIOLOGICAL CHEMISTRY. June 6, 2014; 289(23):16508–16515. DOI: https://doi.org/10.1074/jbc.M114.558098 [PMid:24711459 PMCid:PMC4047417]
Cobat A. High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. The Journal of Infectious Diseases. 2010; 201:15–19. DOI: https://doi.org/10.1086/648611 [PMid:19938975]
Global tuberculosis report. World Health Organization [Internet]; 2016. Available from:http://www.who.int/tb/publications/global_report/gtbr2016_executive_summary_ru.pdf?ua=1
Jo Seddon, Kasprowicz V, Walker NF. Procollagen III N-terminal Propeptide and Desmosine are Released by Matrix Destruction in Pulmonary Tuberculosis. The Journal of Infectious Diseases. 15 November 2013; 208:1571–1579. DOI: https://doi.org/10.1093/infdis/jit343 [PMid:23922364 PMCid:PMC3805234]
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.